Shares of Dyne Therapeutics, Inc. (Nasdaq: DYN) plummeted 25% as the biotechnology firm reported early trial data for its experimental therapy for myotonic dystrophy type 1 (DM1), a genetic disorder that leads to muscle weakness. Despite the company's announcement of positive trial results and plans for accelerated approval submissions, investor confidence seemed to falter, sending the stock to its lowest point in a year.
The Waltham, Massachusetts-based company shared results from the Phase 1/2 ACHIEVE trial of its lead candidate DYNE-101, which showed significant splicing correction and functional improvements in DM1 patients. The trial data demonstrated a reduction in DMPK RNA levels, the molecular target of DYNE-101, and robust splicing correction associated with improvements in multiple functional endpoints. The company plans to initiate a global Registrational Expansion Cohort with the potential to support a submission for U.S. Accelerated Approval in the first half of 2026.
Additionally, Dyne Therapeutics is progressing with its DYNE-251 program for Duchenne muscular dystrophy (DMD), aiming for regulatory submission based on dystrophin as a surrogate endpoint. The company expects to complete enrollment in the Registrational Expansion Cohorts for both programs in 2025, with data expected to support regulatory submissions the following year.
Despite these advancements, Dyne's stock experienced a significant drop. Keay Nakae, a Chardan analyst, commented on the trial data, stating, "We are encouraged to see this dose achieve even greater knockdown of the DMPK target at 3, and 6 months. This results in significant splicing correction at 3 months compared to baseline, as measured by the composite alternative splicing index (CASI-22). However, the spice correction at 6 months is not consistent." Dyne's management believes the inconsistency at 6 months may be due to factors such as poor biopsy sampling, missing baseline data, and the small sample size.
Investors may be reacting to the uncertainty around the 6-month splicing correction data, despite the company's explanations and the overall positive trends in functional outcomes. The market response underscores the high stakes and volatility associated with clinical-stage biopharmaceutical development, where investment sentiment can shift rapidly with new data releases.
Dyne Therapeutics remains focused on advancing its therapeutic candidates through clinical development, with the ultimate goal of providing new treatments for patients with genetically driven neuromuscular diseases. The investor event held today at 8:00 a.m. ET may provide further insights into the company's strategy and the potential impact of the recent trial data on its clinical and regulatory pathways.
https://www.investing.com/news/stock-market-news/dyne-therapeutics-stock-tumbles-following-trial-data-93CH-3807301
